Stockscreener 앱 받기
2.24
1.75%
-0.04
Ventyx Biosciences Inc 주식(VTYX)의 최신 뉴스
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider John Nuss Sells 13,161 Shares - MarketBeat
Ventyx Biosciences' chief scientific officer sells $29,682 in stock - Investing.com
Ventyx Biosciences' chief scientific officer sells $29,682 in stock By Investing.com - Investing.com UK
Insiders Enjoy US$190k Return After Buying Ventyx Biosciences Stock - Simply Wall St
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k - Yahoo Finance
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Cryopyrin-associated Periodic Syndromes Market on Track for Major Expansion by 2034, According to DelveInsight | Amgen, Biovitrum, Novartis, Ventyx Biosciences - The Globe and Mail
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Bought by Vestal Point Capital LP - MarketBeat
Sio Capital Management LLC Raises Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Whitney Tilson, Steven Cohen, Scott Bessent, Millennium Management, Paloma Partners, Ventyx Biosciences Inc (VTYX), Vistra Corp (VST), and More - Insider Monkey
Ventyx Biosciences Inc (NASDAQ: VTYX) Jumps 11.35%, Turning Investors Away - Stocks Register
Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock By Investing.com - Investing.com Australia
Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock - Investing.com
Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Price Target at $10.00 - MarketBeat
Thinking about buying stock in Solid Power, Crowdstrike Holdings - GuruFocus.com
Ventyx Biosciences stock hits 52-week low at $1.78 amid market shifts - Investing.com Australia
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully - Simply Wall St
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress - Yahoo Finance
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - The Manila Times
Ventyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Ventyx Biosciences’ (VTYX) “Outperform” Rating Reiterated at Oppenheimer - Defense World
Ventyx Biosciences (NASDAQ:VTYX) Given "Outperform" Rating at Oppenheimer - MarketBeat
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress - The Manila Times
Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com
Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha
Thinking about buying stock in QuickLogic, Ventyx Biosciences, D - GuruFocus.com
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider
Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat
HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK
Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire
Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat
Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com
Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada
VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - US Post News
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 - The Manila Times
Did Ventyx Biosciences Inc (VTYX) perform well in the last session? - US Post News
2.88%
2.65%
자본화:
|
볼륨(24시간):